CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 715 enrolled
Drug / intervention
XIAFLEX / XIAPEXbiological
Likely dose
XIAFLEX / XIAPEX 0.58 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01674634
NCT01674634Phase 3Completed

A Phase 3b Open-label, Historically-controlled Study to Assess the Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures With Palpable Cords

Endo Pharmaceuticals·interventional·Posted Aug 29, 2012·Updated Oct 5, 2017

In Brief

A Phase 3 clinical trial evaluating XIAFLEX / XIAPEX for Dupuytren's Contracture. Completed, enrolled 715 participants across 25 sites.

Detailed Summary

The primary objective of this study is to assess the safety of two concurrent injections of AA4500 into the same hand in subjects with multiple Dupuytren's contractures with palpable cords followed 24 to 72 hours later by a finger extension procedure and compare the rate of occurrence of targeted serious adverse events (tendon rupture/ligament injury and anaphylaxis) to historical rates of the same in clinical studies and post-marketing commercial use. The secondary objective is to evaluate the efficacy of two concurrent injections of AA4500.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 29, 2012
Enrollment StartSep 1, 2012
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.8 years ago

Interventions

XIAFLEX / XIAPEXbiological

injection (0.58 mg after reconstitution with sterile diluent \[0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride\])